Back
Friday, 11 Dec, 2020
Potential COVID-19 antibody drug made by Singapore firm to be tested on 1,305 local, overseas patients (CNA)
A potential COVID-19 antibody drug developed by Singapore-based biotechnology firm Tychan will be tested on 1,305 infected patients locally and abroad, in what would be its final trial before it can be approved for treatment in Singapore. Tychan said on Friday (Dec 11) that it had received approval from the Health Sciences Authority in October to begin Phase 3 of the clinical trial for its monoclonal antibody called TY027.
Original article: Potential COVID-19 antibody drug made by Singapore firm to be tested on 1,305 local, overseas patients (CNA)